Table 6.
Clinical characteristics and chemosensory function change after 4 months of TNF-α inhibitor treatment (n = 12).
| Before Treatment | After Treatment | p-Value | |
|---|---|---|---|
| Age, years | 35.4 ± 11.9 | - | - |
| Gender, women | 4 (33.3%) | - | - |
| Duration of disease, years | 7.3 ± 2.1 | - | - |
| Clinical disease activity grade | 0.004 ** | ||
| Remission | 0 | 3 (25%) | |
| Mild | 3 (25%) | 7 (58.3%) | |
| Moderate–Severe | 9 (75%) | 2 (16.7%) | |
| BMI, kg/m2 | 24.53 ± 5.24 | 24.77 ± 5.07 | <0.001 ** |
| CRP, mg/L | 4.66 ± 4.80 | 2.89 ± 4.53 | 0.49 |
| Blood leucocytes count, GPt/L | 8.81 ± 2.25 | 6.88 ± 2.24 | 0.41 |
| Fecal Calprotectin, µg/g | 2297 ± 4173 | 1339 ± 3127 | <0.001 ** |
| ADS-L depression score | 12.6 ± 6.2 | 16.1 ± 4.9 | 0.020 * |
| TNF-α inhibitor treatment, n (%) | |||
| Infliximab | - | 6 (50%) | |
| Adalimumab | - | 3 (25%) | |
| Golimumab | - | 3 (25%) | |
| Chemosensory function | |||
| Threshold scores | 7.65 ± 1.98 | 8.31 ± 1.92 | 0.42 |
| Discrimination scores | 12.83 ± 1.64 | 13.75 ± 1.36 | 0.09 |
| Identification scores | 13.75 ± 1.22 | 14.25 ± 1.29 | 0.14 |
| TDI scores | 34.23 ± 2.73 | 36.31 ± 2.94 | 0.038 * |
| Taste sprays scores | 3.83 ± 0.39 | 3.92 ± 0.29 | 0.59 |
Results are expressed as mean ± SD or n (%). * p < 0.05; ** p < 0.01.